473 related articles for article (PubMed ID: 21906804)
61. Targeting of porous hybrid silica nanoparticles to cancer cells.
Rosenholm JM; Meinander A; Peuhu E; Niemi R; Eriksson JE; Sahlgren C; Lindén M
ACS Nano; 2009 Jan; 3(1):197-206. PubMed ID: 19206267
[TBL] [Abstract][Full Text] [Related]
62. Mesoporous silica nanoparticles with manipulated microstructures for drug delivery.
Chen Z; Li X; He H; Ren Z; Liu Y; Wang J; Li Z; Shen G; Han G
Colloids Surf B Biointerfaces; 2012 Jun; 95():274-8. PubMed ID: 22494670
[TBL] [Abstract][Full Text] [Related]
63. Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs.
Zhang Y; Wang J; Bai X; Jiang T; Zhang Q; Wang S
Mol Pharm; 2012 Mar; 9(3):505-13. PubMed ID: 22217205
[TBL] [Abstract][Full Text] [Related]
64. Study on the adsorption mechanism of DNA with mesoporous silica nanoparticles in aqueous solution.
Li X; Zhang J; Gu H
Langmuir; 2012 Feb; 28(5):2827-34. PubMed ID: 22182067
[TBL] [Abstract][Full Text] [Related]
65. Synthesis of mesoporous silica nanoparticles.
Wu SH; Mou CY; Lin HP
Chem Soc Rev; 2013 May; 42(9):3862-75. PubMed ID: 23403864
[TBL] [Abstract][Full Text] [Related]
66. Hybrid nanoparticles for drug delivery and bioimaging: mesoporous silica nanoparticles functionalized with carboxyl groups and a near-infrared fluorescent dye.
Xie M; Shi H; Ma K; Shen H; Li B; Shen S; Wang X; Jin Y
J Colloid Interface Sci; 2013 Apr; 395():306-14. PubMed ID: 23394807
[TBL] [Abstract][Full Text] [Related]
67. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
[TBL] [Abstract][Full Text] [Related]
68. Core-shell designs of photoluminescent nanodiamonds with porous silica coatings for bioimaging and drug delivery II: application.
Prabhakar N; Näreoja T; von Haartman E; Karaman DŞ; Jiang H; Koho S; Dolenko TA; Hänninen PE; Vlasov DI; Ralchenko VG; Hosomi S; Vlasov II; Sahlgren C; Rosenholm JM
Nanoscale; 2013 May; 5(9):3713-22. PubMed ID: 23493921
[TBL] [Abstract][Full Text] [Related]
69. Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine).
Hwa Kim S; Hoon Jeong J; Chul Cho K; Wan Kim S; Gwan Park T
J Control Release; 2005 May; 104(1):223-32. PubMed ID: 15866348
[TBL] [Abstract][Full Text] [Related]
70. Mechanistic insights into LDL nanoparticle-mediated siRNA delivery.
Jin H; Lovell JF; Chen J; Lin Q; Ding L; Ng KK; Pandey RK; Manoharan M; Zhang Z; Zheng G
Bioconjug Chem; 2012 Jan; 23(1):33-41. PubMed ID: 22142191
[TBL] [Abstract][Full Text] [Related]
71. Novel PEI/Poly-γ-Gutamic Acid Nanoparticles for High Efficient siRNA and Plasmid DNA Co-Delivery.
Peng SF; Hsu HK; Lin CC; Cheng YM; Hsu KH
Molecules; 2017 Jan; 22(1):. PubMed ID: 28054985
[TBL] [Abstract][Full Text] [Related]
72. Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity.
Zintchenko A; Philipp A; Dehshahri A; Wagner E
Bioconjug Chem; 2008 Jul; 19(7):1448-55. PubMed ID: 18553894
[TBL] [Abstract][Full Text] [Related]
73. Facile incorporation of aggregation-induced emission materials into mesoporous silica nanoparticles for intracellular imaging and cancer therapy.
Zhang X; Zhang X; Wang S; Liu M; Zhang Y; Tao L; Wei Y
ACS Appl Mater Interfaces; 2013 Mar; 5(6):1943-7. PubMed ID: 23363527
[TBL] [Abstract][Full Text] [Related]
74. Application of an HIV gp41-derived peptide for enhanced intracellular trafficking of synthetic gene and siRNA delivery vehicles.
Kwon EJ; Bergen JM; Pun SH
Bioconjug Chem; 2008 Apr; 19(4):920-7. PubMed ID: 18376855
[TBL] [Abstract][Full Text] [Related]
75. Surfactant-assisted controlled release of hydrophobic drugs using anionic surfactant templated mesoporous silica nanoparticles.
Tsai CH; Vivero-Escoto JL; Slowing II; Fang IJ; Trewyn BG; Lin VS
Biomaterials; 2011 Sep; 32(26):6234-44. PubMed ID: 21684000
[TBL] [Abstract][Full Text] [Related]
76. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression.
Huang HY; Kuo WT; Chou MJ; Huang YY
J Biomed Mater Res A; 2011 Jun; 97(3):330-8. PubMed ID: 21465641
[TBL] [Abstract][Full Text] [Related]
77. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate.
Kim SH; Mok H; Jeong JH; Kim SW; Park TG
Bioconjug Chem; 2006; 17(1):241-4. PubMed ID: 16417275
[TBL] [Abstract][Full Text] [Related]
78. Macroporous silica nanoparticles for delivering Bcl2-function converting peptide to treat multidrug resistant-cancer cells.
Xu W; Ge P; Niu B; Zhang X; Liu J; Xie J
J Colloid Interface Sci; 2018 Oct; 527():141-150. PubMed ID: 29787950
[TBL] [Abstract][Full Text] [Related]
79. NIR-to-visible upconversion nanoparticles for fluorescent labeling and targeted delivery of siRNA.
Jiang S; Zhang Y; Lim KM; Sim EK; Ye L
Nanotechnology; 2009 Apr; 20(15):155101. PubMed ID: 19420539
[TBL] [Abstract][Full Text] [Related]
80. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells.
Yu M; Jambhrunkar S; Thorn P; Chen J; Gu W; Yu C
Nanoscale; 2013 Jan; 5(1):178-83. PubMed ID: 23076766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
